| General Information | |
|---|---|
| ZINC ID | ZINC000058592336 |
| Molecular Weight (Da) | 510 |
| SMILES | CC(C)(C)c1nnc(-c2nn(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)c2Cn2cncn2)s1 |
| Molecular Formula | C24Cl2N7S1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 143.114 |
| HBA | 5 |
| HBD | 0 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 34 |
| LogP | 5.82 |
| Activity (Ki) in nM | 1.9498 |
| Polar Surface Area (PSA) | 102.55 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | - |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.107 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 27 |
| Fraction csp3 | 0.21 |
| Ilogp | 4.35 |
| Xlogp3 | 6.33 |
| Wlogp | 6.3 |
| Mlogp | 4.34 |
| Silicos-it log p | 5.91 |
| Consensus log p | 5.45 |
| Esol log s | -7.18 |
| Esol solubility (mg/ml) | 0.0000334 |
| Esol solubility (mol/l) | 6.54E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.27 |
| Ali solubility (mg/ml) | 0.00000272 |
| Ali solubility (mol/l) | 5.33E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.3 |
| Silicos-it solubility (mg/ml) | 0.00000025 |
| Silicos-it solubility (mol/l) | 5.02E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.92 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 4.09 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.656 |
| Logd | 5.255 |
| Logp | 5.235 |
| F (20%) | 0.001 |
| F (30%) | 0.006 |
| Mdck | - |
| Ppb | 98.07% |
| Vdss | 2.67 |
| Fu | 2.89% |
| Cyp1a2-inh | 0.298 |
| Cyp1a2-sub | 0.162 |
| Cyp2c19-inh | 0.916 |
| Cyp2c19-sub | 0.094 |
| Cl | 3.862 |
| T12 | 0.043 |
| H-ht | 0.379 |
| Dili | 0.994 |
| Roa | 0.38 |
| Fdamdd | 0.06 |
| Skinsen | 0.166 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.38 |
| Bcf | 2.093 |
| Igc50 | 4.057 |
| Lc50 | 5.883 |
| Lc50dm | 4.549 |
| Nr-ar | 0.02 |
| Nr-ar-lbd | 0.415 |
| Nr-ahr | 0.847 |
| Nr-aromatase | 0.996 |
| Nr-er | 0.859 |
| Nr-er-lbd | 0.81 |
| Nr-ppar-gamma | 0.954 |
| Sr-are | 0.949 |
| Sr-atad5 | 0.122 |
| Sr-hse | 0.088 |
| Sr-mmp | 0.972 |
| Sr-p53 | 0.886 |
| Vol | 475.149 |
| Dense | 1.071 |
| Flex | 0.222 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 3 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.277 |
| Synth | 2.864 |
| Fsp3 | 0.208 |
| Mce-18 | 29 |
| Natural product-likeness | -1.782 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |